Literature DB >> 25483082

Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Paulina Podszywalow-Bartnicka1, Magdalena Wolczyk, Monika Kusio-Kobialka, Kamila Wolanin, Krzysztof Skowronek, Margaret Nieborowska-Skorska, Yashodhara Dasgupta, Tomasz Skorski, Katarzyna Piwocka.   

Abstract

BRCA1 tumor suppressor regulates crucial cellular processes involved in DNA damage repair and cell cycle control. We showed that expression of BCR-ABL1 correlates with decreased level of BRCA1 protein, which promoted aberrant mitoses and aneuploidy as well as altered DNA damage response. Using polysome profiling and luciferase-BRCA1 3'UTR reporter system here we demonstrate that downregulation of BRCA1 protein in CML is caused by inhibition of BRCA1 mRNA translation, but not by increased protein degradation or reduction of mRNA level and half-life. We investigated 2 mRNA-binding proteins - HuR and TIAR showing specificity to AU-Rich Element (ARE) sites in 3'UTR of mRNA. BCR-ABL1 promoted cytosolic localization of TIAR and HuR, their binding to BRCA1 mRNA and formation of the TIAR-HuR complex. HuR protein positively regulated BRCA1 mRNA stability and translation, conversely TIAR negatively regulated BRCA1 translation and was found localized predominantly in the cytosolic stress granules in CML cells. TIAR-dependent downregulation of BRCA1 protein level was a result of ER stress, which is activated in BCR-ABL1 expressing cells, as we previously shown. Silencing of TIAR in CML cells strongly elevated BRCA1 level. Altogether, we determined that TIAR-mediated repression of BRCA1 mRNA translation is responsible for downregulation of BRCA1 protein level in BCR-ABL1 -positive leukemia cells. This mechanism may contribute to genomic instability and provide justification for targeting PARP1 and/or RAD52 to induce synthetic lethality in "BRCAness" CML and BCR-ABL1 -positive ALL cells.

Entities:  

Keywords:  ARE, AU-rich element; ATM, Ataxia telangiectasia mutated kinase; ATR, Ataxia telangiectasia and Rad3-related kinase; BCR-ABL; BRCA1; BRCA1, Breast cancer type 1 susceptibility; CML, chronic myeloid leukemia; DNA damage response; HuR; HuR, Hu antigen R (alternative name: ELAV-like protein 1); TIAR; TIAR, TIA1 cytotoxic granule-associated RNA-binding protein-like 1; UPR, unfolded protein response; UTR, untranslated region; cell cycle; eIF, eukaryotic initiation factor; mRNA binding protein; stress response; synthetic lethality; translation

Mesh:

Substances:

Year:  2014        PMID: 25483082     DOI: 10.4161/15384101.2014.965013

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  22 in total

Review 1.  T-cell intracellular antigens in health and disease.

Authors:  Carmen Sánchez-Jiménez; José M Izquierdo
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

3.  Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Authors:  Margaret Nieborowska-Skorska; Silvia Maifrede; Min Ye; Monika Toma; Elizabeth Hewlett; John Gordon; Bac Viet Le; Tomasz Sliwinski; Huaqing Zhao; Katarzyna Piwocka; Peter Valent; Alexei V Tulin; Wayne Childers; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2018-10-02

4.  Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.

Authors:  Gurushankar Chandramouly; Shane McDevitt; Katherine Sullivan; Tatiana Kent; Antonio Luz; J Fraser Glickman; Mark Andrake; Tomasz Skorski; Richard T Pomerantz
Journal:  Chem Biol       Date:  2015-11-05

5.  PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.

Authors:  Paulina Podszywalow-Bartnicka; Silvia Maifrede; Bac Viet Le; Margaret Nieborowska-Skorska; Katarzyna Piwocka; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2018-06-22

6.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Authors:  Margaret Nieborowska-Skorska; Katherine Sullivan; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Grazyna Hoser; Silvia Maifrede; Esteban Martinez; Daniela Di Marcantonio; Elisabeth Bolton-Gillespie; Kimberly Cramer-Morales; Jaewong Lee; Min Li; Artur Slupianek; Daniel Gritsyuk; Sabine Cerny-Reiterer; Ilona Seferynska; Tomasz Stoklosa; Lars Bullinger; Huaqing Zhao; Vera Gorbunova; Katarzyna Piwocka; Peter Valent; Curt I Civin; Markus Muschen; John E Dick; Jean Cy Wang; Smita Bhatia; Ravi Bhatia; Kolja Eppert; Mark D Minden; Stephen M Sykes; Tomasz Skorski
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

7.  Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.

Authors:  Katherine Sullivan; Kimberly Cramer-Morales; Daniel L McElroy; David A Ostrov; Kimberly Haas; Wayne Childers; Robert Hromas; Tomasz Skorski
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

8.  Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.

Authors:  Fei Huang; Nadish Goyal; Katherine Sullivan; Kritika Hanamshet; Mikir Patel; Olga M Mazina; Charles X Wang; W Frank An; James Spoonamore; Shailesh Metkar; Kyle A Emmitte; Simon Cocklin; Tomasz Skorski; Alexander V Mazin
Journal:  Nucleic Acids Res       Date:  2016-02-11       Impact factor: 16.971

9.  Discovering the 3' UTR-mediated regulation of alpha-synuclein.

Authors:  Domenica Marchese; Teresa Botta-Orfila; Davide Cirillo; Juan Antonio Rodriguez; Carmen Maria Livi; Rubén Fernández-Santiago; Mario Ezquerra; Maria J Martí; Elias Bechara; Gian Gaetano Tartaglia
Journal:  Nucleic Acids Res       Date:  2017-12-15       Impact factor: 16.971

10.  Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.

Authors:  Jing Luo; Xinchi Dai; Hua Hu; Jie Chen; Lujun Zhao; Changyong Yang; Jifeng Sun; Lianmin Zhang; Qian Wang; Shilei Xu; Yue Xu; Ningbo Liu; Guoguang Ying; Ping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.